Major depressive disorder is a leading cause of disability worldwide, and evidence suggests a strong genetic basis for its pathophysiology and treatment. Around 50% of patients do not achieve symptom remission following an initial antidepressant treatment, and there are no validated biomarkers of treatment response routinely used in clinics. While numerous pharmacogenetic tools have been developed to assist clinicians in the task of choosing the ideal antidepressant(s) for a given patient, emerging evidence suggests a key role for epigenetic markers, such as DNA methylation, in the prediction of antidepressant response. In this chapter we discuss recent clinical and preclinical findings of an association between epigenetic mechanisms and response to antidepressant treatment, as well as current limitations and future directions for the field of pharmacoepigenetics of depression.
|Original language||English (US)|
|Title of host publication||Pharmacoepigenetics|
|Number of pages||8|
|State||Published - Jan 1 2019|
- DNA methylation
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)